Topic Hub
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 15 of 15 clinical reviews.
A clinician-reviewed guide for caregivers administering MOTS-c peptide to adolescents aged 12 to 17, covering dosing rationale, injection technique, safety monitoring, and when to contact a provider.
Read clinical reviewA clinician-reviewed deep dive into how the mitochondrial peptide MOTS-c affects adolescent development, metabolism, and safety in ages 12 to 17, with primary-source citations and a clear framework for clinical decision-making.
Read clinical reviewA clinically detailed guide to MOTS-c use in adolescents aged 12 to 17, covering school performance, physical activity, dosing caution, and the research gaps that make pediatric use premature outside monitored trials.
Read clinical reviewA clinician-reviewed guide to MOTS-c mitochondrial peptide use in adults 65 and older, covering dosing, safety, metabolic benefits, and how to transition aging patients into a structured peptide therapy program.
Read clinical reviewA complete clinical guide for caregivers helping adults aged 65 and older use MOTS-c mitochondrial peptide, covering injection technique, dose timing, storage, safety monitoring, and when to call a provider.
Read clinical reviewA clinical deep-dive into how the mitochondrial peptide MOTS-c affects aging biology, muscle, metabolic function, and cognitive health in adults 65 and older, with trial data and dosing context.
Read clinical reviewA clinician-reviewed guide to MOTS-c use in adults 65 and older, covering physical activity integration, cognitive engagement, dosing context, safety signals, and evidence from human and animal trials.
Read clinical reviewA clinical overview of MOTS-c mitochondrial peptide use in adolescents ages 12 to 17, covering the evidence base, safety unknowns, regulatory status, and what clinicians and families need to understand before considering off-label administration.
Read clinical reviewA clinician-reviewed guide to MOTS-c peptide use in adolescents aged 12 to 17, covering the evidence base, safety considerations, and how to plan a medically supervised transition to adult care.
Read clinical reviewA clinician-reviewed guide to off-label MOTS-c use in geriatric patients, covering the mitochondrial biology, available human and animal data, dosing protocols, safety signals, and what to discuss with your prescribing provider.
Read clinical reviewMOTS-c is an experimental mitochondrial peptide with zero pediatric clinical trial data. This evidence review explains why off-label use in children under 12 carries serious unknowns and what the current science actually shows.
Read clinical reviewA clinician-reviewed guide to MOTS-c mitochondrial peptide in pediatric patients under 12, covering current evidence, safety data, regulatory status, and what a structured transition to adult endocrinology care looks like.
Read clinical reviewA clinician-reviewed guide to MOTS-c use in children under 12, covering school performance, physical activity, mitochondrial biology, and the complete absence of pediatric safety data.
Read clinical reviewComplete caregiver guidance on MOTS-c mitochondrial peptide administration in children under 12, including dosing considerations, safety data, injection technique, and when to contact a prescriber.
Read clinical reviewA thorough clinical review of MOTS-c mitochondrial peptide use in children under 12, covering developmental biology, current evidence, safety concerns, and why no pediatric dosing protocol exists yet.
Read clinical review